In vitro and in vivo evaluation of 11C ... - ACS Publications

Article Cite This: J. Med. Chem. 2018, 61, 2278−2291

pubs.acs.org/jmc

In Vitro and in Vivo Evaluation of 11C‑Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies Ran Cheng,†,‡,○ Wakana Mori,§,○ Longle Ma,† Mireille Alhouayek,∥ Akiko Hatori,§ Yiding Zhang,§ Daisuke Ogasawara,⊥ Gengyang Yuan,†,# Zhen Chen,† Xiaofei Zhang,† Hang Shi,† Tomoteru Yamasaki,§ Lin Xie,§ Katsushi Kumata,§ Masayuki Fujinaga,§ Yuji Nagai,∇ Takafumi Minamimoto,∇ Mona Svensson,∥ Lu Wang,† Yunfei Du,‡ Mary Jo Ondrechen,# Neil Vasdev,† Benjamin F. Cravatt,⊥ Christopher Fowler,∥ Ming-Rong Zhang,*,§ and Steven H. Liang*,† †

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States ‡ School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, China § Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan ∥ Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden ⊥ The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107 10550 North Torrey Pines Road, La Jolla, California 92037, United States # Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States ∇ Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan S Supporting Information *

ABSTRACT: Monoacylglycerol lipase (MAGL) is the principle enzyme for metabolizing endogenous cannabinoid ligand 2arachidonoyglycerol (2-AG). Blockade of MAGL increases 2-AG levels, resulting in subsequent activation of the endocannabinoid system, and has emerged as a novel therapeutic strategy to treat drug addiction, inflammation, and neurodegenerative diseases. Herein we report a new series of MAGL inhibitors, which were radiolabeled by site-specific labeling technologies, including 11Ccarbonylation and spirocyclic iodonium ylide (SCIDY) radiofluorination. The lead compound [11C]10 (MAGL-0519) demonstrated high specific binding and selectivity in vitro and in vivo. We also observed unexpected washout kinetics with these irreversible radiotracers, in which in vivo evidence for turnover of the covalent residue was unveiled between MAGL and azetidine carboxylates. This work may lead to new directions for drug discovery and PET tracer development based on azetidine carboxylate inhibitor scaffold.

■

INTRODUCTION

example, CB1 agonism has been demonstrated to exert analgesic properties,9−11 while CB1 antagonism has reduced the risks of type II diabetes and cardiovascular disease.12−16 However, a series of adverse effects, including damage to cognition and motor function as well as abuse liability, are also the result of this direct CB1 intervention, thereby hindering their application as therapeutic agents.17,18 As endogenous ligands of eCB, AEA and 2-AG are biosynthesized and released “on request” from membrane lipid precursors in vivo and are primarily deactivated through hydrolysis catalyzed by fatty acid amide hydrolase (FAAH, for AEA),19−21 and monoacylglycerol

The endocannabinoid system (eCB) is a lipid signaling network throughout the central nervous system (CNS) and peripheral nervous system, which consists of two G-protein-coupled cannabinoid receptors, CB1 and CB2, and their corresponding ligands, anandamide (AEA) and 2-arachidonoyglycerol (2AG).1−5 Studies have shown that the eCB dysfunction is involved in a wide spectrum of neuropathological disorders, such as obesity, immunological dysfunction, metabolic syndromes, psychiatric conditions, and neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.6−8 Early efforts toward pharmacotherapies for eCB dysfunction have been focused on direct CB1 modulation, and this approach has generated several favorable results. For © 2018 American Chemical Society

Received: September 21, 2017 Published: February 26, 2018 2278

DOI: 10.1021/acs.jmedchem.7b01400 J. Med. Chem. 2018, 61, 2278−2291

Journal of Medicinal Chemistry

Article

Scheme 1. Synthesis of MAGL Inhibitors 8−11a

Conditions: (i) Et3N, HBTU, 100 °C, DMF, 5 h, 94% yield for 3; 98% yield for 4; 92% yield for 5; 99% yield for 6; 94% yield for 7; (ii) TFA, DCM, rt, overnight; (iii) 1,1,1,3,3,3-hexafluoropropanol, 4-nitrophenyl chloroformate, pyridine, DMAP, Et3N, DCM, 0 °C to rt, overnight, 85% yield for 8 over two steps; 63% yield for 9; 81% yield for 10; 65% yield for 11; 73% yield for 12. HBTU = O-benzotriazol-1-yl-N,N,N′,N′tetramethyluronium hexafluorophosphate; DMF = N,N-dimethylformamide; DMAP = 4-dimethylaminopyridine; DCM = dichloromethane. a

Figure 1. Inhibitory properties of lead compound 10: (A) concentration−response curves for inhibition of 0.5 μM [3H]2-OG hydrolysis by rat brain MAGL, either without or with 60 min preincubation; (B) time-dependency of [3H]2-OG (0.5 μM) hydrolysis under three different concentrations (0.2, 0.6, and 1 nM) of 10 preincubated for the times shown; (C) the kinetics of inhibition by the compound (I, inhibitor 10) in the absence of preincubation and using a short incubation time (2 min); (D) the inhibition of 0.5 μM [3H]2-OG hydrolysis found by the compound in the absence of preincubation (white and orange bars) or in its presence after 60 min of preincubation followed by dilution to reduce the free concentration 20fold (blue bar). For a reversible compound, the blue bar should match the corresponding white bar. Data are the mean ± SEM, n = 3−4 unless otherwise shown.

lipase (MAGL, for 2-AG).22,23 In particular, blockage of MAGL gives rise to increased 2-AG levels, thus enhancing endocannabinoid signaling.24 MAGL inhibition also reduces levels of arachidonic acid (AA), a pain and inflammationinducing prostaglandin precursor, and provides protection against neuroinflammation and neurodegenerative diseases.25−29 Therefore, MAGL-based pharmacotherapy may provide an alternative and effective approach30 to stimulate eCB and beneficial treatment in pain, anxiety, inflammation, neurodegeneration, and cancer,29,31−34 without significant adverse effects, for example, mobility and cognition associated with direct CB1 modulations.4,25,35 Positron emission tomography (PET), a noninvasive molecular imaging modality, is ideal for quantifying eCB activity and density in vivo under normal and disease conditions with minimal perturbation of the biological state.36−39 PET also enables the study of pharmacokinetic

profiles in vivo, including uptake, distribution, and clearance via use of isotopologues of lead compounds that target the eCB pathway. In contrast to FAAH PET tracers that have advanced to clinical PET research imaging studies, i.e., [11C]CURB40 and [11C]MK-3168,41,42 the development of MAGL-targeting PET tracers is still in its infancy. In recent years, considerable efforts have been implemented to radiolabeled MAGL inhibitors, including [11C]JZL184 and [11C]JJKK-048.43 However, these compounds exhibit insufficient brain uptake and failed to advance PET imaging studies in vivo. To the best of our knowledge, only two potential MAGL PET tracers, namely, [ 11 C]SAR127303 44−46 and [11C]MA-PB-1,47 have been advanced to PET imaging studies in higher species (nonhuman primates, NHPs). As a result, unmet need of MAGLspecific PET tracers for human use combined with therapeutic potential of MAGL-modulating pharmacotherapy provides a 2279



Article

Table 1. Binding Affinity and Physicochemical Properties of Compounds 8−11i

a

Determined by [3H]2-OG hydrolysis assay using rat brain membrane with 0 or 60 min preincubation (MAGL inhibitor JZL184 as positive control). Determined by human recombinant MAGL assay (MAGL inhibitor JZL195 as positive control). cDetermined by [3H]AEA hydrolysis assay using rat brain membrane with 0 or 60 min preincubation (FAAH inhibitors URB597 and DOPP as positive controls). dDetermined by ABPP assay on rat brain membrane (MJN110 as positive control). eDetermined by agonist and antagonist CB1 and CB2 receptor assays (CP55940 as positive control in CB1/CB2 agonist assays, rimonabant as positive control in CB1 antagonist assay, and SR144528 as positive control in CB2 antagonist assay). f Calculated by ChemBioDraw Ultra 14.0. gMeasured by “shake-flask” method quantified by LC−MS. hDetermined by PgP-Glo assay. Test compounds (1 μM) with ≤30% changes of luminescence signal (vs vehicle) are defined as “low PgP efflux liability”; verapamil was used as positive control. iAll data are acquired in average of 3−5 runs. ND, not determined. b

hydrolysis of tritiated 2-AG analog [3H]2-oleoylglycerol ([3H]2-OG) was determined at 0 or 60 min preincubation time using our previously reported protocol (Figure 1 and Figure S1 in Supporting Information).54 In particular, the inhibitory properties of the most potent MAGL inhibitor 10 were thoroughly profiled, including (i) excellent binding affinity toward MAGL (Figure 1A, IC 50 = 3.9 nM without preincubation; IC50 = 0.68 nM with 60 min of preincubation), (ii) time-dependent inhibition at the tested concentrations of inhibitor 10 (0.2, 0.6, and 1 nM) of 10 (Figure 1B), (iii) apparent noncompetitive inhibition (Ki = 1.03 nM) of [3H]2OG hydrolysis (Figure 1C), presumably due to covalent interaction occurring even during the short incubation time used, and (iv) irreversible binding mechanism as evidenced by dilution experiments (Figure 1D) and time course studies by activity based protein profiling (ABPP)55 assay (Figure S2, Supporting Information). As shown in Table 1, the two most potent compounds 8 and 10 were further screened in human recombinant MAGL (hMAGL) assay (Figure S3, Supporting Information) and FAAH [3H]AEA hydrolysis binding assay (Figure S4, Supporting Information). While both compounds showed excellent inhibition with IC50 values of 8 (13.4 nM) and 10 (12.7 nM) in the hMAGL assay, only compound 10 represented an excellent starting point with reasonable selectivity toward MAGL over FAAH (30- to 50-fold; Figure S4, Supporting Information). No significant interactions of 10 were observed among two major cannabinoid receptors, CB1/ CB2 (up to 30 μM concentration, Table 1 and Figure S5, Supporting Information), and two other serine hydrolases, ABHD6 and ABHD12 (up to 10 μM concentration, Table 1 and Figure S6, Supporting Information), that can contribute to the catabolism of 2-AG in the brain. We also investigated the interaction of compound 10 with MAGL by molecular docking studies, the assumption being made that the initial interaction, not experimentally measurable due to the rapid formation of the covalent bond, is competitive in nature (Figure 1). The goal is to identify possible molecular interaction between MAGL inhibitors and binding domain based on the fact that excellent low nanomolar binding affinities (0.68−4.2 nM) were identified. Our approach was established upon the reported high-resolution structure of the ligand− protein complex with noncovalent inhibitor (PDB code 3PE6).56 The noncovalent binding modes were first established via both Glide SP57 and XP58 methods (Glide, Schrödinger). To account for the binding site flexibility, the binding

strong stimulus to advance PET tracer development for this target. As part of our ongoing interest in the development of MAGL-targeting PET tracers,44,46,48 we explore a new class of MAGL inhibitors bearing azetidine scaffold, a privileged structure not only frequently used in drug discovery49−51 but also demonstrated as an effective way to reduce lipophilicity in recent MAGL therapeutics.52 Herein we describe our medicinal chemistry efforts to identify and synthesize a small array of azetidinyl carboxylate MAGL inhibitors that are amenable for radiolabeling with carbon-11 or fluorine-18. Preliminary pharmacological evaluation and physiochemical properties of these molecules were determined to select the most promising MAGL inhibitor 10 (MAGL-0519) for further in vivo evaluation by PET. Utilizing site-specific 11C- and 18F-labeling strategies, we were able to not only evaluate brain permeability and specificity of radiolabeled compounds but also evaluate in vivo binding kinetics in rodents and NHPs by PET to shed light on designed azetidinyl carboxylate-based MAGL inhibitors and PET tracers.

■

RESULTS AND DISCUSSION Chemistry. A set of azetidinyl carbamates 8−11 and their corresponding labeling precursors were designed with special emphasis on reduced lipophilicity52 and suitability for radiolabeling with carbon-11 or fluorine-18. As summarized in Scheme 1, condensation of substituted N′-hydroxybenzimidamide 1 and Boc-protected amino acid 2 triggered by HBTU successfully afforded desired oxadiazoles 3−6 in excellent yields (92−99%) by minor modifications of reported procedures.53 The hexafluoropropanoxy leaving moiety was introduced to the oxadiazoles 3−6 to form candidate MAGL inhibitors 8−11 in 63−85% yields following our previously reported strategy.46 The procedure entailed deprotection of the Boc group with trifluoroacetic acid followed by 4-nitrophenyl chloroformate mediated coupling of the corresponding secondary amine with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) in the presence of pyridine and DMAP. The iodinated compound 12 was also synthesized in 69% yield using an analogous procedure, which is designed for 18F-radiolabeling (see Radiochemistry section). In brief, the synthesis of lead compounds 8−11 was achieved efficiently in three steps from commercially available 1 and 2 with overall yields of 62−80%. Pharmacology and Physicochemical Properties. The ability of candidate compounds 8−11 to inhibit MAGL 2280



Article

Scheme 2. Site-Specific 11C-Labeling of (A) Compound 10 and (B) Compound 8a

Conditions: (i) 11CH3I, NaOH, DMF, 70 °C, 5 min, 13% RCY; (ii) HFIP, PMP, THF, rt, then (iii) azetidine generated from 5 after Boc deprotection, THF, 30 °C, 3 min, 11% RCY; (iv) mCPBA, CHCl3, overnight, then SPIAd, 10% Na2CO3, EtOH, 5 h, 56% yield; (v) [18F]TEAB, DMF, 100 °C, 10 min, 28% RCY; (vi) azetidine generated from 3 after Boc deprotection, THF, 30 °C, 3 min, 13% RCY. See Experimental Section for details. RCY = decay-corrected radiochemical yield; HFIP = 1,1,1,3,3,3-hexafluoro-2-propanol; PMP = 1,2,2,6,6-pentamethylpiperidine; THF = tetrahydrofuran; TEAF = tetraethylammonium fluoride.

a

interaction was further studied through Glide/induced fit docking (IFD) runs.59 In general, IFD binding modes were found to show an optimized network of enzyme−ligand interactions as compared to the rigid docking results. The lead compound 10 showed a Glide XP docking score of −8.0 kcal/mol. The covalent docking results were obtained using Glide covalent docking,60 and the estimated free-binding energy values were calculated using Prime MM/GBSA.61 Compound 10 exhibited a predicted covalent docking affinity of −7.40 kcal/mol and ΔGbind of −44.03 kcal/mol. The resulting covalent binding complex was further refined via MarcoModel energy minimization to give the final binding pose (section 2, Supporting Information).61,62 Lipophilicity of candidate compounds can be used as a predictive factor for blood−brain barrier permeability with a favorable range between 1.0 and 3.5.63−65 The cLogP values of compounds 8−11 were predicted to be 2.90, 2.90, 2.80, and 2.80, respectively (Table 1). By use of liquid−liquid partition between n-octanol and water (“shake flask method”),66 the log P values for 8−11 were determined to be 1.45 ± 0.01, 1.42 ± 0.11, 1.23 ± 0.10, and 1.17 ± 0.14, respectively (n = 3). The candidate compounds 8−11 were also evaluated in PgPATPase assay to determine their interaction with recombinant human PgP membranes using verapamil as positive control. No significant response (99% radiochemical purity (n = 3). The specific activity was greater than 3 Ci/μmol (110 GBq/μmol). Another site-specific radiosynthesis of 16 ([carbonyl-11C]10) was also performed based on our previously reported procedure 46 using [11C]COCl2 (Scheme 2A, right). Reaction of [11C]COCl2 with HFIP generated 11C-carbonate 14 in the presence of 1,2,2,6,6-pentamethylpiperidine (PMP) in THF. Addition of the corresponding azetidine (generated from 5) at 30 °C for 3 min afforded 16 in an average RCY of 11%, relative to starting [11C]CO2 at end of synthesis. The specific activity was high (>56 GBq/μmol; 1.5 Ci/μmol), and radiochemical purity was greater than 99%. Both 15 and 16 showed no signs of radiolysis up to 90 min after formulation. To demonstrate the diversity of radiolabeling and evaluate brain permeability of fluorinated MAGL inhibitors, we also carried out 18F- and 11C-isotopologue labeling of 8. The corresponding spirocyclic iodonium ylide (SCIDY)70 precursor 17 for 18F-labeling was obtained from the oxidation of iodinated compound 12, followed by ligand exchange with SPIAd71 in 56% yield (Scheme 2B). The labeled compound 18 ([18F]8) was obtained in 28% RCY, using our SCIDY method,70−75 and 19 ([carbonyl-11C]8) was generated in 13% RCY using analogous [11C]COCl2 protocol46 (Scheme 2B). Despite the fact that compound 19 exhibited high brain permeability (∼1.4 peak SUV, standardized uptake value; Figure S8, Supporting Information), further evaluation of this fluorinated scaffold, i.e., 18 and 19, was not pursued due to its limited in vitro selectivity between MAGL and FAAH. On the basis of its potency and selectivity, 11C-labeled 10 was selected to undergo subsequent evaluation by in vivo PET imaging and ex vivo biodistribution studies in rodents. Preliminary PET Imaging Studies in Rat Brain. Dynamic PET acquisitions were carried out with 15 and 16 in SpragueDawley rats for 90 min. Representative PET images (coronal 2281



Article

Figure 2. Representative PET images (0−90 min) and time−activity curves of 16 in rat brain: (A) baseline (n = 3); (B) blocking studies using KML29 (3 mg/kg pretreatment, 30 min iv before injection, n = 3); (C) self-blocking studies using nonradioactive 10 (3 mg/kg pretreatment, 30 min iv before injection, n = 3); (D) displacement studies using KML29 (3 mg/kg displacement, 15 min iv after injection, indicated by black arrow); (E) chase studies using nonradioactive 10 (3 mg/kg displacement, 15 min iv after injection, indicated by black arrow).

and sagittal, summed images 0−90 min) in whole brain and time−activity curves are shown in Figure 2 and Figure S9 (Supporting Information), respectively. 15 rapidly crossed the blood−brain barrier (>1 SUV) with heterogeneous distribution consistent with MAGL expression in rat brain (Figure S9, Supporting Information).46,76 Pretreatment with nonradioactive 10 (self-blocking; 3 mg/kg iv) remarkably decreased whole brain uptake (∼40% reduction calculated by area under curve, AUC) and showed reasonable clearance of nonspecific binding (SUV2/40min ≈ 3; Figure S9, Supporting Information). However, contrary to typical irreversibly binding covalent (“suicide”) inhibitors that have been developed as radiotracers, which display characteristic plateaued time−activity curves,46,67,77 we observed slow washout (ratio of SUV5min/ SUV90min ≈ 2) of bound radioactivity, which led us to initially question in vivo stability of 11C-methyl group of 10 before the implementation of blocking studies with other structurally diverse MAGL inhibitors. We next investigated if site-specific labeling of 11C-carbonyl position of 10, i.e., compound 16, would display different in vivo kinetics and shed insight on the mechanism of binding. The distribution of 16 was heterogeneous with decreasing order from striatum, cerebellum, cerebral cortex to pons. The distribution pattern of 16 was consistent with the distribution of MAGL in rat brain (Figure 2A).46,76 As shown in Figure 2B, pretreatment with a MAGL inhibitor KML2978 (3 mg/kg, 30 min iv before injection) resulted in average 50% reduction in whole brain uptake by AUC (Figure S10, Supporting Information). Pretreatment studies with nonradioactive 10 (3 mg/kg, 30 min iv before injection) also significantly decreased uptake in the selected brain regions (average 50% reduction in whole brain by AUC, Figure S11, Supporting Information) and abolished the difference of uptakes in different regions, including striatum, cerebellum,

cerebral cortex, and pons (Figure 2C). Blocking studies with a FAAH inhibitor URB59779 (3 mg/kg, 30 min iv before injection) showed no significant reduction (Figure S12, Supporting Information) in brain uptake, as predicted for this selective MAGL inhibitor 10. These results confirmed that 16 has a high level of in vivo specific binding to MAGL. To our surprise, a similar washout pattern to that seen for 15 (cf. Figure S9) was also observed with 16, which argues against instability of the 11C-methyl group as being responsible for the kinetics. In consequence, we investigated the in vivo reversibility of 16 binding to MAGL. We next performed displacement (“chase”) studies using KML29 or nonradioactive 10 (3 mg/kg iv for both cases) at 15 min postinjection of 16 (Figure 2D and Figure 2E). Nearly identical time−activity curves were found between control and chase studies, which supports the expected irreversible binding mechanism of 16 to MAGL. These results further support our hypothesis that the unexpected clearance of 16 in rat brain is thus presumably due to in vivo dissociation of the azetidine carbonyl and the target serine residue of MAGL. PET imaging studies utilizing 16 not only unveiled unexpected kinetics that are likely caused by the azetidinyl carbamate moiety but also may provide a semiquantitative method to measure in vivo dissociation rates (turnover of the covalent adduct) between the azetidinyl scaffold and MAGL; i.e., in this case, the dissociation rate can be expressed by the ratio between SUV5min and SUV90min (the value is ∼2). We also carried out radiometabolite analysis in mouse brain and found that more than 90% radioactivity was irreversibly bound to the brain at 5 and 30 min after injection of 16 (Table S1, Supporting Information). These results together with blocking studies, in a large extent, diminished the possibility that the unexpected washout was caused by brain 2282



Article

Figure 3. (A) Ex vivo biodistribution in mice at five different time points (1, 5, 15, 30, and 60 min) after injection of compound 16. Comparison of bound activity washout between [11C]SAR127303 and compound 16 in two MAGL-rich tissues: (B) adrenal glands and (c) brown adipose tissue. All data are the mean ± SD, n = 3−5. Statistical significance was determined with two-way ANOVA or Student’s t test: (∗) p < 0.05, (∗∗) p ≤ 0.01, and (∗∗∗) p ≤ 0.001.

Figure 4. (A) Representative PET images (0−90 min) and (B) time−activity curves of 16 in NHP brain.

the peripheral organs was consistent with that of prior report of high MAGL expression in the heart, lungs, adrenal glands, and BAT.46 We also carried out blocking studies using KML29 (3 mg/kg), and high specific binding was observed in peripheral MAGL-rich organs, including but not limited to heart, lungs, BAT, kidneys, brain, and adrenal glands (Figure S13). In order to determine whether the dissociation between 16 and MAGL is restricted to the brain, we examined washout rate of bound activities in two peripheral MAGL-rich organs, namely, adrenal glands and BAT, and compared it with that of a known irreversible MAGL tracer, [11C]SAR127303.45,46 The uptake of the two tracers in adrenal and BAT was plotted at 15, 30, and 60 min after injection (Figure 3B and Figure 3C), the results of which indicated the target dissociation of 16 was systematic and time-dependent.

penetrant radiometabolites that are not irreversibly binding or not binding at all to MAGL. Whole Body ex Vivo Biodistribution Studies. The uptake, distribution and clearance of 16 were studied in mice at five time points (1, 5, 15, 30, and 60 min) after injection of the radiotracer (Figure 3A and Tables S2 and S3, Supporting Information). High uptake (>3% ID/g) was observed in several organs including heart, lungs, pancreas, adrenal glands, kidneys, small intestine, and brown adipose tissue (BAT) at 1 and 5 min after injection. After the initial uptake, the radioactivity in all tissues of interest decreased rapidly, while the signals in the heart, lungs, adrenal glands, kidneys, and brown adipose tissue remained at a high level (>3% ID/g). The radioactivity was efficiently cleared from blood (1/60 min ratio of 3.2), and high radioactivity in the kidneys, liver, and small intestine indicated urinary and hepatobiliary elimination. The distribution of 16 in 2283



Article

Lipophilicity was calculated by ChemBioDraw Ultra 14.0 (CambridgeSoft Corporation, PerkinElmer, USA). All tested MAGL inhibitors showed purity of more than 95% as determined by reverse-phase HPLC (Cosmosil C18 column (4.6 mm i.d. × 250 mm); mobile phase MeOH/H2O (v/v, 75/25); flow rate 1.0 mL/min and detection wavelength 254 nm). The lead compounds 8−11 did not show any promiscuous moieties in the pan assay interference compounds assay (PAINS) using two independent in silico filters.80 The animal experiments were approved by the Institutional Animal Care and Use Committee of Massachusetts General Hospital or the Animal Ethics Committee at the National Institutes for Quantum and Radiological Science and Technology, National Institute of Radiological Sciences. Ddy mice (male; 7 weeks, 34−36 g), and SpragueDawley rats (male; 7 weeks; 210−230 g) were kept on a 12 h light/12 h dark cycle and were allowed food and water ad libitum. Chemistry. General Procedure for Synthesis of Compounds 3−6. Et3N (4 mmol) was added to a solution of 1 (2 mmol) and the appropriate Boc-protected amino acid 2 (2.4 mmol) in DMF (10 mL). HBTU (2.4 mmol) was then added to the resulting mixture at room temperature and stirred at 100 °C overnight. Upon the completion of reaction monitored by TLC, the solution was partitioned between ethyl acetate and water. The organic layer was washed several times with saturated aqueous LiBr solution. The aqueous solution was then extracted with ethyl acetate, and the combined organic layers were washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3/1 hexanes/ EtOAc) to give the desired product. Preparation of tert-Butyl 3-(3-(4-Fluorophenyl)-1,2,4-oxadiazol5-yl)azetidine-1-carboxylate (3). Compound 3 was prepared in 94% yield as a white solid. Melting point: 92−94 °C. 1H NMR (300 MHz, CDCl3) δ 8.16−8.01 (m, 2H), 7.23−7.12 (m, 2H), 4.45−4.26 (m, 4H), 4.10−3.98 (m, 1H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 179.1, 167.8, 164.6 (d, J = 251.9 Hz), 155.9, 129.6 (d, J = 8.8 Hz), 122.7 (d, J = 3.3 Hz), 116.1 (d, J = 22.1 Hz), 80.2, 53.1, 28.3, 25.7; 19F NMR (282 MHz, CDCl3) δ −108.1. HRMS (m/z): [M + H]+ calculated for C16H19FN3O3+, 320.1410, found 320.1407. Preparation of tert-Butyl 3-(3-(3-Fluorophenyl)-1,2,4-oxadiazol5-yl)azetidine-1-carboxylate (4). Compound 4 was prepared in 98% yield as a white solid. Melting point: 75−77 °C. 1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 7.8, 1.0 Hz, 1H), 7.83−7.75 (m, 1H), 7.47 (dd, J = 13.8, 8.0 Hz, 1H), 7.25−7.17 (m, 1H), 4.45−4.27 (m, 4H), 4.12− 3.99 (m, 1H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 179.3, 167.7 (d, J = 3.0 Hz), 162.9 (d, J = 246.9 Hz), 155.9, 130.6 (d, J = 8.1 Hz), 128.5 (d, J = 8.5 Hz), 123.2 (d, J = 3.2 Hz), 118.3 (d, J = 21.2 Hz), 114.5 (d, J = 23.7 Hz), 80.2, 53.1, 28.3, 25.7; 19F NMR (282 MHz, CDCl3) δ −111.8. Characterization confirmed by comparison with published characterization data.53 Preparation of tert-Butyl 3-(3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (5). Compound 5 was prepared in 92% yield as a white solid. Melting point: 67−69 °C. 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 4.33 (dt, J = 14.7, 8.7 Hz, 4H), 4.07−3.97 (m, 1H), 3.86 (s, 1H), 1.46 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 178.6, 168.2, 162.0, 155.9, 129.0, 118.9, 114.3, 80.1, 55.4, 55.3, 28.3, 25.7. Preparation of tert-Butyl 3-(3-(3-Methoxyphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (6). Compound 6 was prepared in 99% yield as a white solid. Melting point: 62−64 °C. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 7.6 Hz, 1H), 7.62−7.57 (m, 1H), 7.38 (td, J = 8.2, 2.1 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 4.40−4.29 (m, 4H), 4.08−4.00 (m, 1H), 3.87 (s, 3H), 1.46 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 178.9, 168.5, 159.9, 155.8, 123.0, 127.6, 119.9, 117.8, 112.0, 80.2, 55.4, 55.3, 28.3, 25.7. Preparation of tert-Butyl 3-(3-(4-Iodophenyl)-1,2,4-oxadiazol-5yl)azetidine-1-carboxylate (7). Compound 7 was prepared in a manner similar to that described for 3−6 in 94% yield as a white solid. Melting point: 109−110 °C. 1H NMR (300 MHz, CDCl3) δ 7.90− 7.76 (m, 4H), 4.47−4.26 (m, 4H), 4.10−3.98 (m, 1H), 1.47 (s, 9H); 13 C NMR (75 MHz, CDCl3) δ 179.2, 168.0, 155.9, 138.1, 128.9, 126.0,

Preliminary PET Imaging Studies in Non-Human Primate. As binding affinities of compounds targeting MAGL are known to differ among species,28 our efforts focused on preliminary PET imaging of 16 in higher species, i.e., NHPs to investigate brain permeability, regional distribution, and particularly washout kinetics. Representative PET images in NHP brain are shown in Figure 4A. 16 is brain penetrant with peak brain uptake greater than 1.5 SUV. The distribution was heterogeneous with the highest uptake observed in the decreasing order of occipital cortex (1.7 SUV), striatum (1.5 SUV), cerebellum (1.3 SUV) and the lowest uptake observed in pons (1.1 SUV), which is consistent with MAGL distribution.76 The plasma metabolism was rapid with unchanged 16 fraction, 33% at 1 min, 7% at 15 min, and 1% at 15 min, respectively, with only one other more polar metabolite observed. In terms of washout kinetics, the radioactivity peaked 2 min after injection, then slowly cleared out over 90 min with ratio of ∼3 between SUV5min and SUV90min, which confirmed in vivo dissociation of the radiolabeled azetidine scaffold and MAGL in the living brain (Figure 4B).

■

CONCLUSION An array of azetidinyl carbamates targeting MAGL were efficiently synthesized, among which compound 10 (MAGL0519) was identified as the most promising inhibitor. Potency, selectivity, and irreversible binding mechanism were determined in vitro by MAGL hydrolysis assays, ABPP, CB1/CB2 agonist and antagonist assays, and dilution experiments. Physiochemical properties including lipophilicity (log P) and PgP efflux liability were also measured, and these studies demonstrated that 10 is an excellent new leading scaffold for exploration as a MAGL inhibitor. Diverse radiolabeling strategies, including site specific 11C-labeling and SCIDY radiofluorination method, were employed to provide 11C- or 18 F-isotopologues of MAGL inhibitors in excellent radiochemical yields and high radiochemical purity. The pharmacokinetic profile including brain uptake, clearance, binding specificity, and irreversibility was evaluated by PET and ex vivo whole body distribution in rodents and further supported by proof-of-concept NHP imaging studies. While 16 showed moderate-to-high in vitro and in vivo specific binding and irreversible binding mechanism, further optimization to overcome unexpected washout is needed. As a result, this work not only offers a new roadmap for medicinal chemistry efforts toward new azetidine carboxylate-based MAGL PET tracers with improved metabolic stability but also enables in vivo PET imaging studies in drug discovery toward MAGL inhibitors.

■

EXPERIMENTAL SECTION

General Consideration. All the chemicals employed in the syntheses were purchased from commercial vendors and used without further purification. Thin-layer chromatography (TLC) was conducted with 0.25 mm silica gel plates (60F254) and visualized by exposure to UV light (254 nm) or stained with potassium permanganate. Flash column chromatography was performed using silica gel (particle size 0.040−0.063 mm). Nuclear magnetic resonance (NMR) spectra were obtained either on a Bruker spectrometer 300 MHz or on a Bruker spectrometer 400 MHz. Chemical shifts (δ) are reported in ppm, and coupling constants are reported in hertz. The multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, sept = setpet, m = multiplet, br = broad signal, dd = doublet of doublets. For mass spectrometer measurement, the ionization method is ESI using Agilent 6430 Triple Quad LC/MS. 2284



Article

98.1, 80.2, 53.1, 28.3, 25.7. HRMS (m/z): [M + H]+ calculated for C16H19IN3O3+, 428.0471, found 428.0470. General Procedure for Synthesis of MAGL Inhibitors 8−11. Trifluoroacetic acid (40 mmol) was added to a solution of oxadiazoles 3−6 (2 mmol) in CH2Cl2 (8 mL). The mixture was stirred at ambient temperature overnight. Upon the completion of reactions, the mixture was neutralized with saturated aqueous Na2CO3 and extracted with ethyl acetate (15 mL × 3). The combined organic layers were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue could be used in the next steps without extra purification. A solution of 4-nitrophenyl chloroformate (4 mmol) in CH2Cl2 (15 mL) was added dropwise to a solution of 1,1,1,3,3,3hexafluoro-2-propanol (10 mmol), pyridine (10 mmol), and 4dimethylaminopyridine (0.24 mmol) in CH2Cl2 (15 mL) at 0 °C under argon. The mixture was stirred at ambient temperature overnight, followed by the addition of amine (4 mmol) obtained in previous step and triethylamine (12 mmol) in CH2Cl2 (5 mL). The mixture was stirred at ambient temperature for 8 h, then evaporated to dryness and redissolved in ethyl acetate (100 mL). The organic phase was washed with H2O (100 mL × 4), 1 M aqueous potassium carbonate solution (100 mL), and brine (100 mL). The combined organic layers were dried over MgSO4 and evaporated to dryness. The residue was purified by chromatography on silica gel, elution being carried out with a 1:9 mixture of ethyl acetate and hexanes. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (8). Compound 8 was prepared in 85% yield for two steps as a white solid. Melting point: 45−46 °C. 1H NMR (300 MHz, CDCl3) δ 8.27−7.93 (m, 2H), 7.24−7.13 (m, 2H), 5.68 (sept, J = 6.2 Hz, 1H), 4.69−4.43 (m, 4H), 4.21 (tt, J = 9.0, 6.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 178.0, 167.9, 164.7 (d, J = 252.2 Hz), 151.5, 129.6 (d, J = 8.8 Hz), 122.4 (d, J = 3.3 Hz), 120.6 (q, J = 280.9 Hz), 120.5 (q, J = 280.9 Hz), 116.1 (d, J = 22.1 Hz), 67.8 (hept, J = 34.7 Hz), 54.0, 53.4, 26.3; 19F NMR (282 MHz, CDCl3) δ −73.6 (d), −107.8. HRMS (m/z): [M + H]+ calculated for C15H11F7N3O3+, 414.0689, found 414.0690. Retention time = 16.79 min, HPLC k′ = 3.6. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (9). Compound 9 was prepared in 63% yield for two steps as a white solid. Melting point: 38−39 °C. 1H NMR (300 MHz, CDCl3) δ 7.89 (ddd, J = 7.7, 1.4, 1.0 Hz, 1H), 7.80 (ddd, J = 9.4, 2.4, 1.6 Hz, 1H), 7.48 (td, J = 8.0, 5.7 Hz, 1H), 7.22 (ddd, J = 8.4, 2.6, 1.0 Hz, 1H), 5.68 (hept, J = 6.2 Hz, 1H), 4.69−4.45 (m, 4H), 4.22 (tt, J = 9.0, 6.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 178.2, 167.8 (d, J = 3.1 Hz), 162.9 (d, J = 247.1 Hz), 151.5, 130.7 (d, J = 8.1 Hz), 128.2 (d, J = 8.5 Hz), 123.2 (d, J = 3.2 Hz), 120.6 (q, J = 280.7 Hz), 120.5 (q, J = 280.7 Hz), 118.5 (d, J = 21.2 Hz), 114.5 (d, J = 23.8 Hz), 67.7 (hept, J = 34.6 Hz), 54.0, 53.4, 26.3; 19F NMR (282 MHz, CDCl3) δ −73.6 (d), −111.6. HRMS (m/z): [M + H]+ calculated for C15H11F7N3O3+, 414.0689, found 414.0691. Retention time = 18.38 min, HPLC k′ = 4.0. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (10). Compound 10 was prepared in 81% yield for two steps as a white solid. Melting point: 84−85 °C. 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 5.68 (sept, J = 6.2 Hz, 1H), 4.68−4.39 (m, 4H), 4.27−4.10 (m, 1H), 3.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 177.6, 168.4, 162.2, 151.5, 129.1, 120.6 (q, J = 284.8 Hz), 120.5 (q, J = 284.8 Hz), 118.7, 114.4, 67.8 (hept, J = 34.8 Hz), 55.4, 54.1, 53.5, 26.3. 19F NMR (376 MHz, CDCl3) δ −73.6 (d). HRMS (m/z): [M + H]+ calculated for C16H14F6N3O4+, 426.0889, found 426.0887. Retention time = 16.09 min, HPLC k′ = 3.4. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (11). Compound 11 was prepared in 65% yield for two steps as a white solid. Melting point: 78−80 °C. 1H NMR (400 MHz, CDCl3) δ 7.69 (dt, J = 7.7, 1.0 Hz, 1H), 7.63−7.59 (m, 1H), 7.41 (t, J = 8.0 Hz, 1H), 7.07 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 5.68 (sept, J = 6.2 Hz, 1H), 4.69− 4.48 (m, 4H), 4.29−4.14 (m, 1H), 3.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 177.9, 168.7, 160.0, 151.5, 130.1, 127.4, 120.6 (q, J = 284.7

Hz), 120.5 (q, J = 284.7 Hz), 119.9, 118.0, 112.0, 67.8 (hept, 34.8 Hz), 55.5, 54.1, 53.4, 26.3. 19F NMR (376 MHz, CDCl3) δ −73.6 (d). HRMS (m/z): [M + H]+ calculated for C16H14F6N3O4+, 426.0889, found 426.0890. Retention time = 16.72 min, HPLC k′ = 3.6. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4-Iodophenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (12). Compound 12 was prepared in a manner similar to that described for 8−11 in 73% yield for two steps as a white solid. Melting point: 86−87 °C. 1H NMR (300 MHz, DMSO) δ 7.95 (d, J = 8.6 Hz, 2H), 7.79 (d, J = 8.6 Hz, 2H), 6.56 (sept, J = 6.4 Hz, 1H), 4.61−4.20 (m, 5H); 13C NMR (75 MHz, DMSO) δ 180.1, 167.6, 151.5, 138.7, 129.2, 126.0, 121.2 (q, J = 282.7 Hz), 121.1 (q, J = 282.7 Hz), 99.5, 67.3 (hept, J = 33.4 Hz), 54.3, 53.7, 26.3; 19F NMR (282 MHz, DMSO) δ −72.8 (d). HRMS (m/z): [M + H]+ calculated for C15H11F6IN3O3+, 521.9749, found 521.9747. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4-Hydroxyphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (13). Hexafluorocarbamate compound 10 (0.213 g, 0.5 mmol) was dissolved in DCM (2.5 mL) and cooled to 0 °C. To this solution was added BBr3 (3 mL, 1.0 M in DCM, 3 mmol) dropwise at 0 °C, and the mixture was gradually warmed up to room temperature. The reaction was kept at room temperature until the completion of the reaction as determined by TLC. The reaction mixture was quenched with water (10 mL) and was extracted with DCM (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 mL) and subsequently dried with Na2SO4. The solution was concentrated under reduced pressure and the resulting residue purified via silica gel chromatography. Compound 13 was prepared in 78% yield as a white solid. Melting point: 163−164 °C. 1H NMR (400 MHz, DMSO) δ 10.16 (br s, 1H), 7.86 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 5.69 (sept, J = 6.4 Hz, 1H), 4.62−4.42 (m, 2H), 4.40−4.19 (m, 3H); 13C NMR (100 MHz, DMSO) δ 179.3, 168.0, 160.9, 151.6, 129.3, 120.3 (q, JC−F = 282.6 Hz), 120.2 (q, JC−F = 282.6 Hz), 117.2, 116.4, 67.4 (hept, JC−F = 34.8 Hz), 54.4, 53.8, 26.3. 19F NMR (376 MHz, DMSO) δ −72.8 (d). HRMS (m/z): [M + H]+ calculated forC15H12F6N3O4+, 412.0732, found 412.0735. Preparation of 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4(((1r,3r,5r,7r)-4′,6′-dioxospiro[adamantane-2,2′-[1,3]dioxan]-5′-ylidene)-l3-iodanyl)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (17). The SCIDY precursor 7 could be obtained with 56% yield in two steps by following our previous reported methods.70−73,75 The aryl iodide 12 could be oxidized in chloroform.70 Without further purification, the resulting intermediate could couple the spirocyclic auxiliaries (SPIAd)71 directly to afford the desired ylide precursor 17. In specific, oxidant mCPBA (1.3 mmol, 77% max content) was added to a solution of aryl iodide 12 (1 mmol) in chloroform (10 mL). The reaction mixture was stirred at room temperature overnight. The solvent was then removed by rotary evaporation. The dried residue was suspended in ethanol (10 mL), and (1r,3r,5r,7r)-spiro[adamantane-2,2′-[1,3]dioxane]-4′,6′-dione (SPIAd, 1 mmol) was added followed by 10% Na2CO3(aq) (w/v, 10 mL, 0.33 M solution). The pH of the reaction mixture was tested and adjusted with Na2CO3 until the reaction pH was >10. The reaction mixture was stirred for 5 h until full conversion of to the iodoinium ylide was determined by TLC. The reaction mixture was then diluted with water and extracted with CH2Cl2. The organic layers were combined and washed with water and brine. The organic layer was dried with anhydrous MgSO4, filtered, and concentrated. The residue was purified by chromatography on silica gel, elution being carried out with 1:1 mixture of ethyl acetate and hexanes. The product was obtained as light yellow solid. Melting point: 48−50 °C. Yield: 56% over two steps. 1H NMR (300 MHz, DMSO) δ 8.08 (d, J = 8.6 Hz, 2H), 7.95 (d, J = 8.6 Hz, 2H), 6.56 (hept, J = 6.6 Hz, 1H), 4.62−4.21 (m, 5H), 2.34 (s, 2H), 1.94 (d, J = 12.6 Hz, 4H), 1.79 (s, 2H), 1.66 (d, J = 10.5 Hz, 6H); 13C NMR (75 MHz, DMSO) δ 180.3, 167.2, 163.0, 151.5, 133.6, 129.7, 128.5, 121.2 (q, J = 280.5 Hz), 121.1 (q, J = 280.5 Hz), 119.6, 105.7, 67.3 (hept, J = 33.4 Hz), 58.0, 54.3, 53.7, 36.9, 35.3, 33.6, 26.4, 26.3; 19F NMR (282 MHz, DMSO) δ −72.8 (d). HRMS (m/z): [M + H]+ calculated for C28H25F6IN3O7+, 756.0641, found 756.0643. 2285



Article

Pharmacology. Hydrolysis of [3H]2-OG and [3H]AEA. The assays were undertaken using cytosolic and membrane preparations, respectively, from rat brain. The hydrolysis was measured using the method of Boldrup et al.,81 whereby test compounds, brain samples, and assay buffer (10 mM Tris-HCl and 1 mM EDTA, pH 7.4) are preincubated for 0−60 min prior to addition of substrate ([3H]2-OG for MAGL, [3H]AEA for FAAH, both obtained from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA)) and diluted with nonradioactive 2-OG and AEA, as appropriate (Cayman Chemical Co., Ann Arbor, MI, USA) to give the final assay concentration (0.5 μM unless otherwise stated, in assay buffer containing 0.125% w/v assay concentration of fatty acid-free bovine serum albumin) in an assay volume of 200 μL. Reactions were stopped by addition of 400 μL of a solution containing 40 mL of active charcoal and 160 mL of 0.5 M HCl. Phases were separated by centrifugation, and the aqueous phase, containing the reaction products, was taken and measured for tritium content using liquid scintillation spectroscopy with quench correction. pIC50 and hence IC50 values were determined on the data expressed as % of control using the log(inhibitor) vs response variable slope algorithm of GraphPad Prism. Using this assay, we have previously reported that [3H]2-OG hydrolysis is inhibited by the selective MAGL inhibitor JZL184 with IC50 values of 350, 12, and 5.8 nM following preincubation for 0, 30, and 60 min, respectively,82 while the hydrolysis of [3H]AEA is completely blocked by 100 nM of the selective FAAH inhibitor URB597.68 MAGL inhibitor JZL184 was used as positive control in [3H]2-OG assay, which gave pIC50 values of 6.46 ± 0.04 (without preincubation) and 8.24 ± 0.02 (60 min preincubation), respectively. FAAH inhibitor DOPP83 was used as positive control in [3H]AEA assay, which generated pIC50 value of 9.09 ± 0.04 (60 min preincubation). All data are acquired in average of 3−4 runs. In Vitro Human Recombinant MAGL Inhibition Enzyme Assays. IC50 values of testing compounds 8 and 10 were determined by literature procedure84 and manufacturer’s instructions from commercially available MAGL inhibitor screening kits (Cayman Chemical, Inc.). JZL195 (4.4 μM) was used as positive control per manufacturer’s instructions, which completely blocked human recombinant MAGL hydrolysis. Dose−response simulation function in GraphPad Prism was used for data processing. All data are acquired in average of 3−5 runs. The results are shown in Table 1 and Figure S3. Binding Affinities to CB1 and CB2 Receptors. CB1 and CB2 binding profiles of 8−11 were determined according to published literatures85,86 and supported by the National Institute of Mental Health’s Psychoactive Drug Screening Program. The detailed procedures “assay protocol book” are listed on the Web site (https://pdspdb.unc.edu/pdspWeb/). In specific, compound CP55940 was used as positive control in CB1/CB2 agonist assays. Rimonabant was used as positive control in CB1 antagonist assay, and SR144528 was used as positive control in CB2 antagonist assay. All data are acquired in average of 3−5 runs. The results are shown in Table 1, and the corresponding dose−response curves are shown in Figure S5 in the Supporting Information. Activity Based Protein Profiling (ABPP). General Procedure.55 Mouse brain membrane proteomes (1 mg/mL) were preincubated with either DMSO or inhibitors (1 μM and 10 μM) at 37 °C. After 30 min, FP-rhodamine (1 μM final concentration) was added, and the mixture was incubated for another 1−180 min at room temperature. Reactions were quenched with 4× SDS loading buffer and run on SDS−PAGE. Samples were visualized by in-gel fluorescence scanning using a ChemiDoc MP system. For time course experiment, proteomes are treated with 1 μM and 10 μM compounds 8−11 for 30 min at 37 °C followed by labeling with FP-Rh (1 μM final concentration) for varying time at room temperature. DMSO is negative control, and MJN110 [2,5-dioxopyrrolidin-1-yl 4-(bis(4chlorophenyl)methyl) piperazine-1-carboxylate],87 a validated irreversible MAGL inhibitor, is positive control. The relative intensity was compared to the DMSO treated proteomes, which were set to 100%. All data are acquired in average of 3 runs. The percentage of enzyme

activity remaining was determined by measuring the integrated optical intensity of the fluorescent protein bands using image lab 5.2.1. Molecular Modeling. Covalent docking was performed with iterative energy minimization in YASARA,88 using as input the output complex structure generated from flexible, noncovalent docking in the Schrödinger suite of programs. Starting with the best pose from flexible, noncovalent docking, a covalent bond was formed in silico in YASARA. Energy minimization, using the YAMBER389 force field, was performed on the covalently bound complex. See section 2 of Supporting Information for details. Radiochemistry. Radiolabeling of 15. [11C]CH3I was synthesized from cyclotron-produced [11C]CO2, which was produced by 14N(p, α)11C nuclear reaction. Briefly, [11C]CO2 was bubbled into a solution of LiAlH4 (0.4 M in THF, 300 μL). After evaporation, the remaining reaction mixture was treated with hydroiodic acid (57% aqueous solution, 300 μL). The resulting [11C]CH3I was transferred under helium gas with heating into a precooled (−15 to −20 °C) reaction vessel containing precursor 13 (1.0 mg), NaOH (4.9 μL, 0.5 M), and anhydrous DMF (300 μL). After the radioactivity reached a plateau during transfer, the reaction vessel was warmed to 70 °C and maintained for 5 min. CH3CN/H2O + 0.1% Et3N (v/v, 75/25, 0.5 mL) was added to the reaction mixture, which was then injected to a semipreparative HPLC system. HPLC purification was completed on a Capcell Pak UG80 C18 column (10 mm i.d. × 250 mm) using a mobile phase of CH3CN/H2O + 0.1% Et3N (v/v,75/25) at a flow rate of 5.0 mL/min. The retention time for 15 was 8.0 min. The radioactive fraction corresponding to the desired product was collected in a sterile flask, evaporated to dryness in vacuo, and reformulated in a saline solution (3 mL) containing 100 μL of 25% ascorbic acid in sterile water and 100 μL of 20% Tween 80 in ethanol. (Note: We added ascorbic acid to prevent potential radiolysis and Tween 80 to improve aqueous solubility.) The synthesis time was ∼30 min from end of bombardment. Radiochemical and chemical purity were measured by analytical HPLC (Capcell Pak UG80 C18, 4.6 mm i.d. × 250 mm, UV at 254 nm; CH3CN/H2O + 0.1% Et3N (v/v, 80/20) at a flow rate of 1.0 mL/min). The identity of 15 was confirmed by the co-injection with unlabeled 10. Radiochemical yield was 13.1 ± 0.2% (n = 3) decay-corrected based on [11C]CO2 with >99% radiochemical purity, and the molar activity was 117.80−254.24 GBq/μmol (3.18−6.73 Ci/ μmol). Radiolabeling of 16. [11C]CO2 was produced by 14N(p, α)11C nuclear reactions in cyclotron and transferred into a preheated methanizer packed with nickel catalyst at 400 °C to produce 11CH4, which was subsequently reacted with chlorine gas at 560 °C to generate [11C]CCl4. [11C]COCl2 was produced via the reactions between [11C]CCl4 and iodine oxide and sulfuric acid46 and trapped in a solution of hexafluoroisopropanol (5.00 mg) and 1,2,2,6,6pentamethylpiperidine (PMP; 5.2 μL) in THF (200 μL) at 0 °C. A solution of azetidine 5 (1.00 mg) and PMP (1.0 μL) in THF (200 μL) was added into the mixture and heated at 30 °C for 3 min before cooling to ambient temperature. The reaction mixtures were concentrated to remove THF, then diluted with HPLC mobile phase (500 μL), followed by the injection on HPLC column. HPLC purification was performed on a Capcell Pak C18 column (10 mm × 250 mm, 5 μm) using a mobile phase of CH3CN/H2O + 0.1% Et3N (75/25, v/v) at a flow rate of 5.0 mL/min. The retention time of 16 was 8.0 min. The product solution was concentrated by evaporation and reformulated in a saline solution (3 mL) containing 100 μL of 25% ascorbic acid in sterile water and 100 μL of 20% Tween 80 in ethanol. (Note: We added ascorbic acid to prevent potential radiolysis and Tween 80 to improve aqueous solubility.) The radiochemical purity and chemical purity were measured by an analytical HPLC (Capcell Pak C18, 4.6 mm × 250 mm, 5 μm). The identity of 16 was confirmed by the co-injection with unlabeled 10. The radiochemical yield was 6% on average (n = 3) decay-corrected based on [11C]CO2 with >99% radiochemical purity, and the molar activity was 60.55− 69.74 GBq/μmol (1.64−1.89 Ci/μmol). Radiofluorination for 18F-Labeled 1,1,1,3,3,3-Hexafluoropropan2-yl 3-(3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate (18). [18F]Fluoride was trapped on an ion exchange cartridge 2286



Article

γ counter (PerkinElmer, USA), and all radioactivity measurements were automatically decay corrected based on half-life of carbon-11. The results are expressed as the percentage of injected dose per gram of wet tissue (% ID/g) or standardized uptake value (SUV). Small-Animal PET Imaging Studies. PET scans were acquired by an Inveon PET scanner (Siemens Medical Solutions, Knoxville, TN, USA). Sprague-Dawley rats were kept under anesthesia with 1− 2% (v/v) isoflurane during the scan. The radiotracer (∼1 mCi/150− 200 μL) was injected via a preinstalled catheter via tail vein. A dynamic scan in 3D list mode was acquired for 90 min. For pretreatment studies, 10 (3 mg/kg), KML29 (3 mg/kg), or URB597 (3 mg/kg) dissolved in 300 μL of saline containing 5% ethanol, 5% DMSO and 5% Tween 80 was injected at 30 min via the tail vein catheter before the injection of 16. For displacement (“chase”) studies, KML29 (3 mg/kg) was injected at 15 min via the tail vein catheter after the injection of 16. As we previously reported,46,90,91 the PET dynamic images were reconstructed using ASIPro VW software (Analysis Tools and System Setup/Diagnostics Tool, Siemens Medical Solutions). Volumes of interest, including the whole brain, cerebral cortex, cerebellum, striatum, thalamus, and pons were placed referencing the MRI template software. The radioactivity was decay-corrected and expressed as the standardized uptake value. SUV = (radioactivity per mL tissue/injected radioactivity) × body weight. Extent of Irreversible Binding for Brain Homogenate. Following the intravenous injection of 16, Ddy mice (n = 3) were sacrificed at 5 and 30 min after injection, respectively. The mouse brain was quickly removed and homogenized in an ice-cooled CH3CN/H2O (v/v 1/1, 1 mL) solution. The homogenate was centrifuged at 150 000 rpm for 5 min at 4 °C, and the supernatant was collected. The supernatants were carefully decanted, and the pellets were resuspended in the same volume of extraction solvent. The procedure was repeated in triplicate. The combined supernatants from each mouse were weighed and aliquots counted for radioactivity. Each pellet was also counted for radioactivity. The percentage of bound activity in the brain was calculated based on literature procedures.67,68 PET Study in Non-Human Primates. A male rhesus monkey (weight range 5.26−5.72 kg) underwent PET scan (Hamamatsu SHR7700 animal PET scanner) while awake. A solution of 16 (3.70−3.71 mCi) in saline was injected into the monkey via a flexible percutaneous venous catheter, followed by a 90 min dynamic PET scan with the head centered in the field of view. The co-registration of PET image to individual MR image was based on a literature method.92 The same parameter was used for the transformation of co-registered PET image into the brain template MR and for the individual MR image. Each ROI was delineated on the brain template MR image. Time−activity curves were extracted from the corresponding ROIs, and brain uptake of radioactivity was decay-corrected to the time of injection and expressed as SUV.

(Waters QMA, part no. 186004540) from 18O-enriched water and subsequently released with a solution of tetraethylammonium bicarbonate (TEAB, 3 mg) in 1 mL of CH3CN/H2O (v/v 7:3) into a 5 mL V-shaped vial sealed with a Teflon septum. The solution was evaporated at 110 °C while nitrogen gas was passed through a P2O5Drierite column into the vented vial. The evaporation was repeated three times with addition of dry acetonitrile (1 mL) each time. After that, the dried [18F]fluoride was redissolved in 0.3 mL of dry CH3CN. To an oven-dried vial containing precursor 13 (4.5 mg) and a magnetic stirrer bar was added anhydrous CH3CN (0.3 mL), followed by addition of a solution of [18F]TEAF (tetraethylammonium [18F]fluoride) in CH3CN (0.1 mL). The vial was sealed and heated at 100 °C for 10 min. After the reaction completed, mixture aliquot was taken for analysis by radio-TLC (eluent, ethyl acetate) for radiochemical conversion (RCC). TLC plates (silica gel 60, 10 cm × 2 cm) were spotted with an aliquot (2−5 μL) of crude reaction mixture approximately 1.5 cm from the bottom of the plate (baseline). TLC plates were developed in a chamber containing mixture of ethyl acetate until within 2 cm from the top of the plate (front). Analysis was performed using a Bioscan AR-2000 radio-TLC imaging scanner. Radiochemical identity and purity were determined by radio-HPLC. A Phenomenex Luna C18, 250 mm × 4.6 mm, 10 μm HPLC column was used for the analytical analysis with a Waters 1515 isocratic HPLC pump equipped with a Waters 2487 dual λ absorbance detector, a Bioscan Flow-Count equipped with a NaI crystal, and Breeze software. The flow rate for analytical HPLC analysis was 1 mL/min. Product identity was determined via co-injection with nonradioactive standard, whereas the semipreparative purifications were performed on a Phenomenex Luna C18, 250 mm × 10.0 mm, 10 μm HPLC column with 0.1 M NH4·HCO2 (aq) as mobile phase and the flow rate was 5 mL/min. The radiochemical purity and chemical purity were measured by an analytical HPLC (Phenomenex Luna C18, 4.6 mm × 250 mm, 5 μm). The identity of 18 was confirmed by the co-injection with unlabeled 8. The radiochemical yield was 28 ± 2% (n = 3) decaycorrected based on starting [18F]fluoride with >99% radiochemical purity and the molar activity was greater than 1 Ci/μmol. Radiosynthesis of 11C-Carbonyl Labeled 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)azetidine1-carboxylate (19). [11C]CO2 was produced by 14N(p, α)11C nuclear reactions in cyclotron and transferred into a preheated methanizer packed with nickel catalyst at 400 °C to produce [11C]CH4, which was subsequently reacted with chlorine gas at 560 °C to generate [11C]CCl4. [11C]COCl2 was produced via the reactions between [11C]CCl4 and iodine oxide and sulfuric acid and trapped in a solution of hexafluoroisopropanol (5.00 mg) and 1,2,2,6,6-pentamethylpiperidine (PMP; 5.2 μL) in THF (200 μL) at 0 °C. A solution of azetidine 3 (1.00 mg) and PMP (1.0 μL) in THF (200 μL) was added into the mixture and heated at 30 °C for 3 min before cooling to ambient temperature. The reaction mixtures were concentrated to remove THF, then diluted with HPLC mobile phase (500 μL), followed by the injection on HPLC column. HPLC purification was performed on a Capcell Pak C18 column (10 mm × 250 mm, 5 μm) using a mobile phase of CH3CN/H2O + 0.1% Et3N (75/25, v/v) at a flow rate of 5.0 mL/min. The retention time of 19 was 8.5 min. The product solution was concentrated by evaporation and reformulated in a saline solution (3 mL) containing 100 μL of 25% ascorbic acid in sterile water and 100 μL of 20% Tween 80 in ethanol. The radiochemical purity and chemical purity were measured by an analytical HPLC (Capcell Pak C18, 4.6 mm × 250 mm, 5 μm). The identity of 19 was confirmed by the co-injection with unlabeled 8. The radiochemical yield was 13.1 ± 2.2% (n = 3) decay-corrected based on [11C]CO2 with >99% radiochemical purity, and the molar activity was greater than 1 Ci/μmol. Ex Vivo Biodistribution of 16 in Mice. A solution of 16 (50 μCi/150−200 μL) was injected into Ddy mice via tail vein. These mice (each time point n = 3) were sacrificed at 1, 5, 15, 30, and 60 min after tracer injection. Major organs, including whole brain, heart, liver, lung, spleen, kidneys, small intestine (including contents), muscle, testes, and blood samples, were quickly harvested and weighed. The radioactivity present in these tissues was measured using 1480 Wizard

■

ASSOCIATED CONTENT

S Supporting Information *

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b01400. Characterization of all new compounds and NMR spectra, assay methods, computational docking studies, PET imaging procedures, and supplemental figures and tables (PDF) Crystallographic information (CIF) Molecular formula strings and some data (CSV)

■

AUTHOR INFORMATION

Corresponding Authors

*M.-R.Z.: phone, +81 433 823 709; fax, +81-43-206-3261; email, [email protected]. *S.H.L.: phone, +1 617 726 6107; fax, +1-617-726-6165; email, [email protected]. 2287



Article

ORCID

(7) Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006, 58, 389−462. (8) Bisogno, T.; Di Marzo, V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol. Res. 2007, 56, 428−442. (9) Hohmann, A. G.; Suplita, R. L. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006, 8, E693−708. (10) Agarwal, N.; Pacher, P.; Tegeder, I.; Amaya, F.; Constantin, C. E.; Brenner, G. J.; Rubino, T.; Michalski, C. W.; Marsicano, G.; Monory, K.; Mackie, K.; Marian, C.; Batkai, S.; Parolaro, D.; Fischer, M. J.; Reeh, P.; Kunos, G.; Kress, M.; Lutz, B.; Woolf, C. J.; Kuner, R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007, 10, 870− 879. (11) Jhaveri, M.; Richardson, D.; Chapman, V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 2007, 152, 624−632. (12) Després, J.-P.; Golay, A.; Sjöström, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353, 2121−2134. (13) Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rössner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365, 1389−1397. (14) Pi-Sunyer, F. X.; Aronne, L. J.; Heshmati, H. M.; Devin, J.; Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295, 761−775. (15) Scheen, A. J.; Finer, N.; Hollander, P.; Jensen, M. D.; Van Gaal, L. F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368, 1660−1672. (16) Van Gaal, L. F.; Scheen, A. J.; Rissanen, A. M.; Rössner, S.; Hanotin, C.; Ziegler, O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 2008, 29, 1761−1771. (17) Moreira, F. A.; Grieb, M.; Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res. Clin Endocrinol Metab 2009, 23, 133−144. (18) Owens, B. Drug development: The treasure chest. Nature 2015, 525, S6−S8. (19) Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83− 87. (20) Deutsch, D. G.; Ueda, N.; Yamamoto, S. The fatty acid amide hydrolase (FAAH). Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 201−210. (21) McKinney, M. K.; Cravatt, B. F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 2005, 74, 411−432. (22) Karlsson, M.; Contreras, J. A.; Hellman, U.; Tornqvist, H.; Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. J. Biol. Chem. 1997, 272, 27218−27223. (23) Blankman, J. L.; Simon, G. M.; Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2arachidonoylglycerol. Chem. Biol. 2007, 14, 1347−1356. (24) Makara, J. K.; Mor, M.; Fegley, D.; Szabo, S. I.; Kathuria, S.; Astarita, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T. F.; Piomelli, D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 2005, 8, 1139−1141. (25) Blankman, J. L.; Cravatt, B. F. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 2013, 65, 849−871.

Longle Ma: 0000-0002-6359-4702 Yunfei Du: 0000-0002-0213-2854 Neil Vasdev: 0000-0002-2087-5125 Benjamin F. Cravatt: 0000-0001-5330-3492 Ming-Rong Zhang: 0000-0002-3001-9605 Steven H. Liang: 0000-0003-1413-6315 Author Contributions ○

R.C. and W.M. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■

ACKNOWLEDGMENTS We thank the National Institute of Mental Health’s Psychoactive Drug Screening Program (NIMH PDSP; directed by Bryan L. Roth at the University of North Carolina at Chapel Hill and Jamie Driscoll at NIMH) for in vitro screening. R.C. is supported by China Scholarship Council (Grant 201506250036). M.J.O. acknowledges support from the National Science Foundation under Grants CHE-1305655 and MCB-1517290. N.V. acknowledges the National Institute on Ageing of the NIH for funding (Grant R01AG054473). C.F. acknowledges the Swedish Science Research Council (Grant 12158, Medicine) for funding. B.F.C. acknowledges support from the National Institute on Drug Abuse (NIDA) under Grant DA033760. S.H.L. is a recipient of NIH Career Development Award (Grant DA038000) and Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM, Grant DA043507) from NIDA.

■

ABBREVIATIONS USED PET, positron emission tomography; eCB, endocannabinoid system; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; [3H]2-OG, [3H]2-oleoylglycerol; MAGL, monoacylglycerol lipase; FAAH, fatty acid amide hydrolase; ABPP, activity based protein profiling; SUV, standardized uptake value; TAC, time−activity curve; % ID/g, percentage of injected dose per gram of wet tissue; PgP, P-glycoprotein; BAT, brown adipose tissue; SCIDY, spirocyclic iodonium ylide.

■

REFERENCES

(1) Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and function expression of the cloned cDNA. Nature 1990, 346, 561−564. (2) Cravatt, B. F.; Lichtman, A. H. The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol. 2004, 61, 149−160. (3) Pertwee, R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006, 30, S13−S18. (4) Ahn, K.; McKinney, M. K.; Cravatt, B. F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 2008, 108, 1687−1707. (5) Aaltonen, N.; Ribas, C. R.; Lehtonen, M.; Savinainen, J. R.; Laitinen, J. T. Brain regional cannabinoid CB1 receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice. Eur. J. Pharm. Sci. 2014, 51, 87−95. (6) Di Marzo, V.; Melck, D.; Bisogno, T.; De Petrocellis, L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998, 21, 521−528. 2288



Article

Translational studies with [11C]MK-3168, a PET tracer for fatty acid amide hydrolase (FAAH). J. Nucl. Med. 2012, 53, 397. (43) Hicks, J. W.; Parkes, J.; Tong, J.; Houle, S.; Vasdev, N.; Wilson, A. A. Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors. Nucl. Med. Biol. 2014, 41, 688−694. (44) Wang, L.; Mori, W.; Cheng, R.; Yui, J.; Rotstein, B. H.; Fujinaga, M.; Hatori, A.; Vasdev, N.; Zhang, M.-R.; Liang, S. H. A novel class of sulfonamido [11C-carbonyl]-labeled carbamates and ureas as radiotracers for monoacylglycerol lipase. J. Nucl. Med. 2016, 57, 4. (45) Wang, C.; Placzek, M. S.; Van de Bittner, G. C.; Schroeder, F. A.; Hooker, J. M. A novel radiotracer for imaging monoacylglycerol lipase in the brain using positron emission tomography. ACS Chem. Neurosci. 2016, 7, 484−489. (46) Wang, L.; Mori, W.; Cheng, R.; Yui, J.; Hatori, A.; Ma, L.; Zhang, Y.; Rotstein, B. H.; Fujinaga, M.; Shimoda, Y.; Yamasaki, T.; Xie, L.; Nagai, Y.; Minamimoto, T.; Higuchi, M.; Vasdev, N.; Zhang, M.-R.; Liang, S. H. Synthesis and preclinical evaluation of sulfonamido-based [11C-carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase. Theranostics 2016, 6, 1145−1159. (47) Ahamed, M.; Attili, B.; van Veghel, D.; Ooms, M.; Berben, P.; Celen, S.; Koole, M.; Declercq, L.; Savinainen, J. R.; Laitinen, J. T.; Verbruggen, A.; Bormans, G. Synthesis and preclinical evaluation of [11C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL). Eur. J. Med. Chem. 2017, 136, 104−113. (48) Wang, L.; Fujinaga, M.; Cheng, R.; Yui, J.; Shimoda, Y.; Rotstein, B. H.; Zhang, Y.; Vasdev, N.; Zhang, M.-R.; Liang, S. H. Synthesis and preliminary evaluation of a 11C-labeled piperidin-4-yl azetidine diamide for imaging monoacylglycerol lipase. J. Nucl. Med. 2016, 57, 1044. (49) Ye, X. Y.; Chen, S. Y.; Wu, S.; Yoon, D. S.; Wang, H.; Hong, Z.; O’Connor, S. P.; Li, J.; Li, J. J.; Kennedy, L. J.; Walker, S. J.; Nayeem, A.; Sheriff, S.; Camac, D. M.; Ramamurthy, V.; Morin, P. E.; Zebo, R.; Taylor, J. R.; Morgan, N. N.; Ponticiello, R. P.; Harrity, T.; Apedo, A.; Golla, R.; Seethala, R.; Wang, M.; Harper, T. W.; Sleczka, B. G.; He, B.; Kirby, M.; Leahy, D. K.; Hanson, R. L.; Guo, Z.; Li, Y.-X.; Li, Y. X.; DiMarco, J. D.; Scaringe, R.; Maxwell, B.; Moulin, F.; Barrish, J. C.; Gordon, D. A.; Robl, J. A. Discovery of clinical candidate 2-((2S,6S)-2phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an orally active novel selective 11βhydroxysteroid dehydrogenase type 1 inhibitor. J. Med. Chem. 2017, 60, 4932−4948. (50) Desroy, N.; Housseman, C.; Bock, X.; Joncour, A.; Bienvenu, N.; Cherel, L.; Labeguere, V.; Rondet, E.; Peixoto, C.; Grassot, J.-M.; Picolet, O.; Annoot, D.; Triballeau, N.; Monjardet, A.; Wakselman, E.; Roncoroni, V.; Le Tallec, S.; Blanque, R.; Cottereaux, C.; Vandervoort, N.; Christophe, T.; Mollat, P.; Lamers, M.; Auberval, M.; Hrvacic, B.; Ralic, J.; Oste, L.; van der Aar, E.; Brys, R.; Heckmann, B. Discovery of 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a first-in-class autotaxin inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 2017, 60, 3580−3590. (51) Johansson, A.; Löfberg, C.; Antonsson, M.; von Unge, S.; Hayes, M. A.; Judkins, R.; Ploj, K.; Benthem, L.; Lindén, D.; Brodin, P.; Wennerberg, M.; Fredenwall, M.; Li, L.; Persson, J.; Bergman, R.; Pettersen, A.; Gennemark, P.; Hogner, A. Discovery of (3-(4-(2-oxa-6azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties. J. Med. Chem. 2016, 59, 2497−2511. (52) Butler, C. R.; Beck, E. M.; Harris, A.; Huang, Z.; McAllister, L. A.; am Ende, C. W.; Fennell, K.; Foley, T. L.; Fonseca, K.; Hawrylik, S. J.; Johnson, D. S.; Knafels, J. D.; Mente, S.; Noell, G. S.; Pandit, J.; Phillips, T. B.; Piro, J. R.; Rogers, B. N.; Samad, T. A.; Wang, J.; Wan, S.; Brodney, M. A. Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase. J. Med. Chem. 2017, 60, 9860−9873.

(26) Fowler, C. J. The potential of inhibitors of endocannabinoid metabolism for drug development: A critical review. Handb. Exp. Pharmacol. 2015, 231, 95−128. (27) Kohnz, R. A.; Nomura, D. K. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. Chem. Soc. Rev. 2014, 43, 6859−6869. (28) Labar, G.; Wouters, J.; Lambert, D. M. A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling. Curr. Med. Chem. 2010, 17, 2588−2607. (29) Mulvihill, M. M.; Nomura, D. K. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013, 92, 492−497. (30) Tuo, W.; Leleu-Chavain, N.; Spencer, J.; Sansook, S.; Millet, R.; Chavatte, P. Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors. J. Med. Chem. 2017, 60, 4−46. (31) Long, J. Z.; Li, W.; Booker, L.; Burston, J. J.; Kinsey, S. G.; Schlosburg, J. E.; Pavon, F. J.; Serrano, A. M.; Selley, D. E.; Parsons, L. H.; Lichtman, A. H.; Cravatt, B. F. Selective blockade of 2arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5, 37−44. (32) Nomura, D. K.; Morrison, B. E.; Blankman, J. L.; Long, J. Z.; Kinsey, S. G.; Marcondes, M. C. G.; Ward, A. M.; Hahn, Y. K.; Lichtman, A. H.; Conti, B.; Cravatt, B. F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334, 809−813. (33) Cao, Z.; Mulvihill, M. M.; Mukhopadhyay, P.; Xu, H.; Erdelyi, K.; Hao, E.; Holovac, E.; Hasko, G.; Cravatt, B. F.; Nomura, D. K.; Pacher, P. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144, 808−817. (34) Costola-de-Souza, C.; Ribeiro, A.; Ferraz-de-Paula, V.; Calefi, A. S.; Aloia, T. P.; Gimenes-Junior, J. A.; de Almeida, V. I.; Pinheiro, M. L.; Palermo-Neto, J. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PLoS One 2013, 8, e77706. (35) Fowler, C. J. The potential of inhibitors of endocannabinoid metabolism for drug development: A critical review. In Endocannabinoids; Pertwee, R. G., Ed.; Handbook of Experimental Pharmacology, Vol. 231; Springer: Cham, Switzerland, 2015; pp 95−128, DOI: 10.1007/978-3-319-20825-1_4. (36) Lee, C.-M.; Farde, L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol. Sci. 2006, 27, 310−316. (37) Phelps, M. E. Positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9226−9233. (38) Fowler, J. S.; Wolf, A. P. Working against time: Rapid radiotracer synthesis and imaging the human brain. Acc. Chem. Res. 1997, 30, 181−188. (39) Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S. Molecular imaging in drug development. Nat. Rev. Drug Discovery 2008, 7, 591−607. (40) Rusjan, P. M.; Wilson, A. A.; Mizrahi, R.; Boileau, I.; Chavez, S. E.; Lobaugh, N. J.; Kish, S. J.; Houle, S.; Tong, J. Mapping human brain fatty acid amide hydrolase activity with PET. J. Cereb. Blood Flow Metab. 2013, 33, 407−414. (41) Liu, P.; Hamill, T. G.; Chioda, M.; Chobanian, H.; Fung, S.; Guo, Y.; Chang, L.; Bakshi, R.; Hong, Q.; Dellureficio, J.; Lin, L. S.; Abbadie, C.; Alexander, J.; Jin, H.; Mandala, S.; Shiao, L. L.; Li, W.; Sanabria, S.; Williams, D.; Zeng, Z.; Hajdu, R.; Jochnowitz, N.; Rosenbach, M.; Karanam, B.; Madeira, M.; Salituro, G.; Powell, J.; Xu, L.; Terebetski, J. L.; Leone, J. F.; Miller, P.; Cook, J.; Holahan, M.; Joshi, A.; O’Malley, S.; Purcell, M.; Posavec, D.; Chen, T. B.; Riffel, K.; Williams, M.; Hargreaves, R.; Sullivan, K. A.; Nargund, R. P.; DeVita, R. J. Discovery of MK-3168: A PET tracer for imaging brain fatty acid amide hydrolase. ACS Med. Chem. Lett. 2013, 4, 509−513. (42) Joshi, A.; Li, W.; Sanabria, S.; Holahan, M.; Purcell, M.; Declercq, R.; Depre, M.; Bormans, G.; Van Laere, K.; Hamill, T. 2289



Article

for positron emission tomography radiopharmaceuticals. Chem. Soc. Rev. 2016, 45, 4708−4726. (70) Rotstein, B. H.; Stephenson, N. A.; Vasdev, N.; Liang, S. H. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of nonactivated and hindered aromatics. Nat. Commun. 2014, 5, 4365. (71) Rotstein, B. H.; Wang, L.; Liu, R. Y.; Patteson, J.; Kwan, E. E.; Vasdev, N.; Liang, S. H. Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides. Chem. Sci. 2016, 7, 4407−4417. (72) Stephenson, N. A.; Holland, J. P.; Kassenbrock, A.; Yokell, D. L.; Livni, E.; Liang, S. H.; Vasdev, N. Iodonium ylide-mediated radiofluorination of 18F-FPEB and validation for human use. J. Nucl. Med. 2015, 56, 489−492. (73) Wang, L.; Jacobson, O.; Avdic, D.; Rotstein, B. H.; Weiss, I. D.; Collier, L.; Chen, X.; Vasdev, N.; Liang, S. H. Ortho-stabilized 18Fazido click agents and their application in PET imaging with singlestranded DNA aptamers. Angew. Chem., Int. Ed. 2015, 54, 12777− 12781. (74) Jacobson, O.; Weiss, I. D.; Wang, L.; Wang, Z.; Yang, X.; Dewhurst, A.; Ma, Y.; Zhu, G.; Niu, G.; Kiesewetter, D. O.; Vasdev, N.; Liang, S. H.; Chen, X. 18F-labeled single-stranded DNA aptamer for PET imaging of protein tyrosine kinase-7 expression. J. Nucl. Med. 2015, 56, 1780−1785. (75) Wang, L.; Cheng, R.; Fujinaga, M.; Yang, J.; Zhang, Y.; Hatori, A.; Kumata, K.; Yang, J.; Vasdev, N.; Du, Y.; Ran, C.; Zhang, M. R.; Liang, S. H. A facile radiolabeling of [18F]FDPA via spirocyclic iodonium ylides: Preliminary PET imaging studies in preclinical models of neuroinflammation. J. Med. Chem. 2017, 60, 5222−5227. (76) Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10819−10824. (77) Fowler, J. S.; MacGregor, R. R.; Wolf, A. P.; Arnett, C. D.; Dewey, S. L.; Schlyer, D.; Christman, D.; Logan, J.; Smith, M.; Sachs, H.; Aquilonius, S. M.; Bjurling, P.; Halldin, C.; Hartvig, P.; Leenders, K. L.; Lundqvist, H.; Oreland, L.; Stålnacke, C.-G.; Långström, B. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987, 235, 481−485. (78) Chang, J. W.; Niphakis, M. J.; Lum, K. M.; Cognetta, A. B., 3rd; Wang, C.; Matthews, M. L.; Niessen, S.; Buczynski, M. W.; Parsons, L. H.; Cravatt, B. F. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem. Biol. 2012, 19, 579−588. (79) Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3‘- or 4‘-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure− activity relationships, and molecular modeling studies. J. Med. Chem. 2004, 47, 4998−5008. (80) Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719− 2740. (81) Boldrup, L.; Wilson, S. J.; Barbier, A. J.; Fowler, C. J. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J. Biochem. Biophys. Methods 2004, 60, 171−177. (82) Bjorklund, E.; Noren, E.; Nilsson, J.; Fowler, C. J. Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br. J. Pharmacol. 2010, 161, 1512−1526. (83) Sadovski, O.; Hicks, J. W.; Parkes, J.; Raymond, R.; Nobrega, J.; Houle, S.; Cipriano, M.; Fowler, C. J.; Vasdev, N.; Wilson, A. A. Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorg. Med. Chem. 2013, 21, 4351−4357. (84) Griebel, G.; Pichat, P.; Beeske, S.; Leroy, T.; Redon, N.; Jacquet, A.; Francon, D.; Bert, L.; Even, L.; Lopez-Grancha, M.; Tolstykh, T.; Sun, F.; Yu, Q.; Brittain, S.; Arlt, H.; He, T.; Zhang, B.; Wiederschain,

(53) Patwardhan, N. N.; Morris, E. A.; Kharel, Y.; Raje, M. R.; Gao, M.; Tomsig, J. L.; Lynch, K. R.; Santos, W. L. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J. Med. Chem. 2015, 58, 1879−1899. (54) Hernandez-Torres, G.; Cipriano, M.; Heden, E.; Bjorklund, E.; Canales, A.; Zian, D.; Feliu, A.; Mecha, M.; Guaza, C.; Fowler, C. J.; Ortega-Gutierrez, S.; Lopez-Rodriguez, M. L. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew. Chem., Int. Ed. 2014, 53, 13765−13770. (55) Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 2008, 77, 383−414. (56) Schalk-Hihi, C.; Schubert, C.; Alexander, R.; Bayoumy, S.; Clemente, J. C.; Deckman, I.; DesJarlais, R. L.; Dzordzorme, K. C.; Flores, C. M.; Grasberger, B.; Kranz, J. K.; Lewandowski, F.; Liu, L.; Ma, H.; Maguire, D.; Macielag, M. J.; McDonnell, M. E.; Mezzasalma Haarlander, T.; Miller, R.; Milligan, C.; Reynolds, C.; Kuo, L. C. Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 A resolution. Protein Sci. 2011, 20, 670−683. (57) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739−1749. (58) Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177−6196. (59) Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49, 534−553. (60) Zhu, K.; Borrelli, K. W.; Greenwood, J. R.; Day, T.; Abel, R.; Farid, R. S.; Harder, E. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring. J. Chem. Inf. Model. 2014, 54, 1932−1940. (61) Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 2016, 12, 281−296. (62) Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127−6129. (63) Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 2003, 5, 376−389. (64) Patel, S.; Gibson, R. In vivo site-directed radiotracers: a minireview. Nucl. Med. Biol. 2008, 35, 805−815. (65) Pike, V. W. Considerations in the development of reversibly binding PET radioligands for brain Imaging. Curr. Med. Chem. 2016, 23, 1818−1869. (66) Test No. 107: Partition Coefficient (n-Octanol/Water): Shake Flask Method. Guidelines for the Testing of Chemicals, Section 1; Organisation for Economic Cooperation and Development (OECD): Paris, 1995; DOI: 10.1787/9789264069626-en. (67) Wilson, A. A.; Garcia, A.; Parkes, J.; Houle, S.; Tong, J.; Vasdev, N. [11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl. Med. Biol. 2011, 38, 247−253. (68) Wilson, A. A.; Hicks, J. W.; Sadovski, O.; Parkes, J.; Tong, J.; Houle, S.; Fowler, C. J.; Vasdev, N. Radiosynthesis and evaluation of [11C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography. J. Med. Chem. 2013, 56, 201−209. (69) Rotstein, B. H.; Liang, S. H.; Placzek, M. S.; Hooker, J. M.; Gee, A. D.; Dolle, F.; Wilson, A. A.; Vasdev, N. 11C=O bonds made easily 2290



Article

D.; Bertrand, T.; Houtmann, J.; Rak, A.; Vallee, F.; Michot, N.; Auge, F.; Menet, V.; Bergis, O. E.; George, P.; Avenet, P.; Mikol, V.; Didier, M.; Escoubet, J. Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Sci. Rep. 2015, 5, 7642. (85) Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X. P.; Norval, S.; Sassano, M. F.; Shin, A. I.; Webster, L. A.; Simeons, F. R.; Stojanovski, L.; Prat, A.; Seidah, N. G.; Constam, D. B.; Bickerton, G. R.; Read, K. D.; Wetsel, W. C.; Gilbert, I. H.; Roth, B. L.; Hopkins, A. L. Automated design of ligands to polypharmacological profiles. Nature 2012, 492, 215−220. (86) Kroeze, W. K.; Sassano, M. F.; Huang, X. P.; Lansu, K.; McCorvy, J. D.; Giguere, P. M.; Sciaky, N.; Roth, B. L. PRESTOTango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 2015, 22, 362−369. (87) Niphakis, M. J.; Cognetta, A. B.; Chang, J. W.; Buczynski, M. W.; Parsons, L. H.; Byrne, F.; Burston, J. J.; Chapman, V.; Cravatt, B. F. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem. Neurosci. 2013, 4, 1322−1332. (88) Krieger, E.; Geretti, E.; Brandner, B.; Goger, B.; Wells, T. N.; Kungl, A. J. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations. Proteins: Struct., Funct., Genet. 2004, 54, 768− 775. (89) Krieger, E.; Darden, T.; Nabuurs, S. B.; Finkelstein, A.; Vriend, G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins: Struct., Funct., Genet. 2004, 57, 678−683. (90) Wang, L.; Yui, J.; Wang, Q.; Zhang, Y.; Mori, W.; Shimoda, Y.; Fujinaga, M.; Kumata, K.; Yamasaki, T.; Hatori, A.; Rotstein, B. H.; Collier, T. L.; Ran, C.; Vasdev, N.; Zhang, M.-R.; Liang, S. H. Synthesis and preliminary PET imaging studies of a FAAH radiotracer ([11C]MPPO) based on α-ketoheterocyclic scaffold. ACS Chem. Neurosci. 2016, 7, 109−118. (91) Zhang, X.; Kumata, K.; Yamasaki, T.; Cheng, R.; Hatori, A.; Ma, L.; Zhang, Y.; Xie, L.; Wang, L.; Kang, H. J.; Sheffler, D. J.; Cosford, N. D. P.; Zhang, M. R.; Liang, S. H. Synthesis and preliminary studies of a novel negative allosteric modulator, 7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for imaging of metabotropic glutamate receptor 2. ACS Chem. Neurosci. 2017, 8, 1937−1948. (92) McLaren, D. G.; Kosmatka, K. J.; Oakes, T. R.; Kroenke, C. D.; Kohama, S. G.; Matochik, J. A.; Ingram, D. K.; Johnson, S. C. A population-average MRI-based atlas collection of the rhesus macaque. NeuroImage 2009, 45, 52−59.

2291


In vitro and in vivo evaluation of 11C ... - ACS Publications

Recommend Documents